MACK Annual EBITDA
-$2.18 M
-$2000.00-0.09%
31 December 2023
Summary:
As of February 5, 2025, MACK annual earnings before interest, taxes, depreciation & amortization is -$2.18 million, with the most recent change of -$2000.00 (-0.09%) on December 31, 2023. During the last 3 years, it has risen by +$2.84 million (+56.58%).MACK EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MACK Quarterly EBITDA
-$669.00 K
-$179.00 K-36.53%
01 March 2024
Summary:
As of February 5, 2025, MACK quarterly earnings before interest, taxes, depreciation & amortization is -$669.00 thousand, with the most recent change of -$179.00 thousand (-36.53%) on March 1, 2024. Over the past year, it has dropped by -$138.00 thousand (-25.99%).MACK Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MACK TTM EBITDA
-$2.26 M
-$83.00 K-3.81%
01 March 2024
Summary:
As of February 5, 2025, MACK TTM earnings before interest, taxes, depreciation & amortization is -$2.26 million, with the most recent change of -$83.00 thousand (-3.81%) on March 1, 2024. Over the past year, it has increased by +$34.00 thousand (+1.48%).MACK TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MACK EBITDA Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -0.1% | -26.0% | +1.5% |
3 y3 years | +56.6% | -26.0% | +1.5% |
5 y5 years | +96.6% | -26.0% | +1.5% |
MACK EBITDA High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | ||||||
5 y | 5-year | ||||||
alltime | all time | +0.1% | +41.4% | +10.7% |
Merrimack Pharmaceuticals EBITDA History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2024 | - | -$669.00 K(+36.5%) | -$2.26 M(+3.8%) |
Dec 2023 | -$2.18 M(+0.1%) | -$490.00 K(-7.7%) | -$2.18 M(-5.1%) |
Sept 2023 | - | -$531.00 K(-6.7%) | -$2.29 M(+1.2%) |
June 2023 | - | -$569.00 K(-2.9%) | -$2.27 M(+3.8%) |
Mar 2023 | - | -$586.00 K(-3.5%) | -$2.18 M(+0.4%) |
Dec 2022 | -$2.17 M(-16.9%) | -$607.00 K(+20.4%) | -$2.17 M(+6.6%) |
Sept 2022 | - | -$504.00 K(+3.7%) | -$2.04 M(-5.3%) |
June 2022 | - | -$486.00 K(-15.8%) | -$2.15 M(-11.9%) |
Mar 2022 | - | -$577.00 K(+22.0%) | -$2.45 M(-6.5%) |
Dec 2021 | -$2.62 M(-47.8%) | -$473.00 K(-23.6%) | -$2.62 M(-13.6%) |
Sept 2021 | - | -$619.00 K(-20.4%) | -$3.03 M(-11.4%) |
June 2021 | - | -$778.00 K(+4.3%) | -$3.42 M(-10.6%) |
Mar 2021 | - | -$746.00 K(-15.8%) | -$3.82 M(-23.7%) |
Dec 2020 | -$5.01 M(-73.6%) | -$886.00 K(-12.0%) | -$5.01 M(-20.1%) |
Sept 2020 | - | -$1.01 M(-14.9%) | -$6.27 M(+5.1%) |
June 2020 | - | -$1.18 M(-38.8%) | -$5.97 M(-50.9%) |
Mar 2020 | - | -$1.94 M(-9.8%) | -$12.16 M(-36.0%) |
Dec 2019 | -$18.98 M(-70.1%) | -$2.15 M(+204.4%) | -$18.98 M(-39.3%) |
Sept 2019 | - | -$705.00 K(-90.4%) | -$31.26 M(-32.4%) |
June 2019 | - | -$7.37 M(-15.9%) | -$46.27 M(-16.9%) |
Mar 2019 | - | -$8.76 M(-39.3%) | -$55.65 M(-12.3%) |
Dec 2018 | -$63.43 M(-19.2%) | -$14.43 M(-8.2%) | -$63.43 M(-1.2%) |
Sept 2018 | - | -$15.71 M(-6.2%) | -$64.20 M(+19.9%) |
June 2018 | - | -$16.75 M(+1.3%) | -$53.53 M(-22.4%) |
Mar 2018 | - | -$16.54 M(+8.8%) | -$69.03 M(-12.1%) |
Dec 2017 | -$78.53 M(-44.8%) | -$15.20 M(+201.4%) | -$78.53 M(-24.8%) |
Sept 2017 | - | -$5.04 M(-84.4%) | -$104.42 M(-21.2%) |
June 2017 | - | -$32.25 M(+23.8%) | -$132.59 M(-1.8%) |
Mar 2017 | - | -$26.05 M(-36.6%) | -$134.98 M(-5.1%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Dec 2016 | -$142.16 M(+1.0%) | -$41.09 M(+23.7%) | -$142.16 M(-10.6%) |
Sept 2016 | - | -$33.21 M(-4.1%) | -$158.94 M(-1.5%) |
June 2016 | - | -$34.64 M(+4.3%) | -$161.42 M(+12.0%) |
Mar 2016 | - | -$33.23 M(-42.6%) | -$144.16 M(+3.2%) |
Dec 2015 | -$140.81 M(+126.7%) | -$57.87 M(+62.2%) | -$139.74 M(+61.8%) |
Sept 2015 | - | -$35.68 M(+105.3%) | -$86.38 M(+17.4%) |
June 2015 | - | -$17.38 M(-39.7%) | -$73.58 M(+7.3%) |
Mar 2015 | - | -$28.81 M(+540.1%) | -$68.56 M(+10.4%) |
Dec 2014 | -$62.11 M(-47.0%) | -$4.50 M(-80.3%) | -$62.11 M(-26.8%) |
Sept 2014 | - | -$22.88 M(+85.1%) | -$84.81 M(-12.7%) |
June 2014 | - | -$12.37 M(-44.7%) | -$97.14 M(-14.1%) |
Mar 2014 | - | -$22.36 M(-17.8%) | -$113.11 M(-3.5%) |
Dec 2013 | -$117.16 M(+33.8%) | -$27.21 M(-22.7%) | -$117.16 M(+3.2%) |
Sept 2013 | - | -$35.21 M(+24.2%) | -$113.57 M(+12.4%) |
June 2013 | - | -$28.34 M(+7.3%) | -$101.00 M(+10.1%) |
Mar 2013 | - | -$26.40 M(+11.8%) | -$91.74 M(+4.8%) |
Dec 2012 | -$87.54 M(+16.6%) | -$23.62 M(+4.3%) | -$87.54 M(+9.0%) |
Sept 2012 | - | -$22.64 M(+18.7%) | -$80.31 M(+7.2%) |
June 2012 | - | -$19.08 M(-14.1%) | -$74.95 M(-10.7%) |
Mar 2012 | - | -$22.20 M(+35.4%) | -$83.94 M(+13.5%) |
Dec 2011 | -$75.07 M(+75.4%) | -$16.39 M(-5.1%) | -$73.95 M(+10.4%) |
Sept 2011 | - | -$17.28 M(-38.4%) | -$67.00 M(+9.6%) |
June 2011 | - | -$28.07 M(+129.8%) | -$61.10 M(+38.4%) |
Mar 2011 | - | -$12.21 M(+29.5%) | -$44.13 M(+3.1%) |
Dec 2010 | -$42.80 M(-4.5%) | -$9.43 M(-17.1%) | -$42.80 M(+28.3%) |
Sept 2010 | - | -$11.38 M(+2.5%) | -$33.37 M(+51.8%) |
June 2010 | - | -$11.10 M(+2.0%) | -$21.99 M(+102.0%) |
Mar 2010 | - | -$10.88 M | -$10.88 M |
Dec 2009 | -$44.81 M | - | - |
FAQ
- What is Merrimack Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Merrimack Pharmaceuticals?
- What is Merrimack Pharmaceuticals annual EBITDA year-on-year change?
- What is Merrimack Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Merrimack Pharmaceuticals?
- What is Merrimack Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Merrimack Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Merrimack Pharmaceuticals?
- What is Merrimack Pharmaceuticals TTM EBITDA year-on-year change?
What is Merrimack Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of MACK is -$2.18 M
What is the all time high annual EBITDA for Merrimack Pharmaceuticals?
Merrimack Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is -$2.17 M
What is Merrimack Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, MACK annual earnings before interest, taxes, depreciation & amortization has changed by -$2000.00 (-0.09%)
What is Merrimack Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of MACK is -$669.00 K
What is the all time high quarterly EBITDA for Merrimack Pharmaceuticals?
Merrimack Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$473.00 K
What is Merrimack Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, MACK quarterly earnings before interest, taxes, depreciation & amortization has changed by -$138.00 K (-25.99%)
What is Merrimack Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of MACK is -$2.26 M
What is the all time high TTM EBITDA for Merrimack Pharmaceuticals?
Merrimack Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is -$2.04 M
What is Merrimack Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, MACK TTM earnings before interest, taxes, depreciation & amortization has changed by +$34.00 K (+1.48%)